Duvelisib
Sign in to save this workspacePrimary targets: PI3K · FDA status: FDA Approved
Selectivity scorecard
KISS
100.00
Gini
0.716
CATDS
0.030
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Duvelisib. Strongest target: PDK2_PDHK2 at 42.7% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | PDK2_PDHK2 | 42.7% | 57.3% |
| 2 | CAMKK2 | 34.4% | 65.6% |
| 3 | DNA_PK | 33.4% | 66.6% |
| 4 | PKG2_PRKG2 | 33.3% | 66.7% |
| 5 | VRK1 | 24.2% | 75.8% |
| 6 | P38A_MAPK14 | 21.9% | 78.1% |
| 7 | LYN | 21.7% | 78.3% |
| 8 | STK39_STLK3 | 21.6% | 78.4% |
| 9 | PKMYT1 | 20.3% | 79.7% |
| 10 | GSK3A | 18.7% | 81.3% |
| 11 | AURORA_C | 18.6% | 81.4% |
| 12 | HASPIN | 18.5% | 81.5% |
| 13 | CDK2_CYCLIN_A1 | 18.2% | 81.8% |
| 14 | MUSK | 18.2% | 81.8% |
| 15 | MEKK3 | 17.6% | 82.4% |
| 16 | ITK | 17.5% | 82.5% |
| 17 | ROS_ROS1 | 16.5% | 83.5% |
| 18 | EPHA4 | 15.8% | 84.2% |
| 19 | PKCTHETA | 15.4% | 84.6% |
| 20 | PDK1_PDPK1 | 15.2% | 84.8% |
Selectivity landscape
Where Duvelisib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Duvelisib.
Atlas insights for Duvelisib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 386.31 | |
| ALLOGRAFT_REJECTION | 1092.41 | |
| ANDROGEN_RESPONSE | 404.22 | |
| ANGIOGENESIS | 150.25 | |
| APICAL_JUNCTION | 1103.04 | |
| APICAL_SURFACE | 111.54 | |
| APOPTOSIS | 1127.79 | |
| BILE_ACID_METABOLISM | 158.09 | |
| CHOLESTEROL_HOMEOSTASIS | 148.83 | |
| COAGULATION | 120.06 | |
| COMPLEMENT | 592.74 | |
| DNA_REPAIR | 338.79 | |
| E2F_TARGETS | 1029.36 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 352.61 | |
| ESTROGEN_RESPONSE_EARLY | 458.97 | |
| ESTROGEN_RESPONSE_LATE | 463.57 | |
| FATTY_ACID_METABOLISM | 153.59 | |
| G2M_CHECKPOINT | 881.47 | |
| GLYCOLYSIS | 419.10 | |
| HEDGEHOG_SIGNALING | 113.08 | |
| HEME_METABOLISM | 333.17 | |
| HYPOXIA | 646.13 | |
| IL2_STAT5_SIGNALING | 463.67 | |
| IL6_JAK_STAT3_SIGNALING | 640.07 | |
| INFLAMMATORY_RESPONSE | 693.80 | |
| INTERFERON_ALPHA_RESPONSE | 140.52 | |
| INTERFERON_GAMMA_RESPONSE | 863.75 | |
| KRAS_SIGNALING_DN | 180.33 | |
| KRAS_SIGNALING_UP | 475.99 | |
| MITOTIC_SPINDLE | 871.96 | |
| MTORC1_SIGNALING | 547.86 | |
| MYC_TARGETS_V1 | 686.23 | |
| MYC_TARGETS_V2 | 212.09 | |
| MYOGENESIS | 463.28 | |
| NOTCH_SIGNALING | 78.84 | |
| OXIDATIVE_PHOSPHORYLATION | 143.45 | |
| P53_PATHWAY | 648.03 | |
| PANCREAS_BETA_CELLS | 71.94 | |
| PEROXISOME | 158.46 | |
| PI3K_AKT_MTOR_SIGNALING | 1327.24 | |
| PROTEIN_SECRETION | 244.22 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 45.66 | |
| SPERMATOGENESIS | 409.07 | |
| TGF_BETA_SIGNALING | 294.21 | |
| TNFA_SIGNALING_VIA_NFKB | 768.71 | |
| UNFOLDED_PROTEIN_RESPONSE | 256.36 | |
| UV_RESPONSE_DN | 580.02 | |
| UV_RESPONSE_UP | 500.19 | |
| WNT_BETA_CATENIN_SIGNALING | 347.64 | |
| XENOBIOTIC_METABOLISM | 281.86 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.867 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.854 |
| SRR12202498 | — | 0.840 |
| SRR1443713 | GTEX | 0.835 |
| C3N-03420 | — | 0.834 |
Annotations
Sign in to read and post annotations.
Loading…